FDA Grants Seventh Breakthrough Device Designation for SeaStar's SCD in Sepsis
ICU sits 58% above its 52-week low of $2.07 on elevated volume (3.8× avg).
Summary
The FDA granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) to treat hyperinflammation in adults with sepsis or septic condition. This is the seventh such designation for the SCD platform, underscoring the FDA's recognition of the device's potential in a condition with no approved therapies and high mortality. The designation may accelerate development and review, and the company expects to submit data from the NEUTRALIZE-AKI trial's sepsis subgroup in the near term. SeaStar's cash position is tight at $7.0M as of Q2, so regulatory progress is critical. The news follows a $3.3M warrant exercise on October 5, providing some runway.
At the time of this announcement, ICU was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.1M. The 52-week trading range was $2.07 to $7.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.